Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology ... announces a strategic cooperation with the South Korean BioTech ... a joint venture Medybloom to develop and promote Type ... China . Medytox, the Botulinum ... and is also the fourth company in the world ...
(Date:7/27/2015)... , July 27, 2015   DocResponse ... technology application in a peer-reviewed study , ... triage: audit study", published in the July issue ... study by Harvard Medical School researchers determined that ... DocResponse listing the correct diagnosis first in standardized ...
(Date:7/27/2015)... , Belgium , July 27, ... VNRX), a life sciences company focused on developing blood-based ... and other conditions, today announced that it has engaged ... organization, Global Specimen Solutions, Inc. (GSS), to support initial ... cancer tests. Under the agreement, GSS ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7
... CVM ) announces that its CEL-1000 immunomodulator was ... against the recombinant hepatitis B,virus protein more quickly than ... was seen within 14 days, most pronounced with a ... up to a 40% increase in antibody,signal at day ...
... Ontario, Sept. 19 ArtJen Complexus Holdings,Corp. (http://www.fbcx.com ... trial with obese type 2 diabetics and an animal ... studied by a major US,west-coast university medical center. The ... fiber that binds dietary fat will involve,overweight but not ...
Cached Medicine Technology:CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein 2CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein 3ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx 2
(Date:7/27/2015)... ... July 27, 2015 , ... The ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction ... (AAN). The FSHD care guideline is published today. , This new guideline ...
(Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just ... “The patient is high-end athlete, whose accomplishments include running in 27 triathlons and ... tendon pain, which was diagnosed as tendinitis. I did an ultrasound and found ...
(Date:7/27/2015)... ... 27, 2015 , ... David Gilmour has added additional tour dates ... additional night at each of his original four tour stops in the United States ... Gilmour’s 2016 North America tour dates: , Thursday, March 24, 2016 (3/24/16) at the ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program in ... support its mission of reducing the number of deaths and injuries occurring from police ... their families. PursuitSAFETY works with the police to find better and safer ways ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth loss ... incur a lot of stress, pain, discomfort and embarrassment, which is why they are ... reaps the benefits of implants with the cost savings of dentures for anyone on ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4
... higher levels of a fatty acid known as docosahexaenoic ... lower risk //of developing dementia and Alzheimer’s disease, according ... genetic factors have all been found to increase the ... that causes 70 percent of cases of dementia in ...
... research article published in the Lancet has brought to light ... the Indian //community. With only 2.2percent of the Adult population ... shows that the Indian body constitution is responsible. ... in India between the age groups of 30 and 50 ...
... debilitating neurological disorder called Guillain-Barre syndrome in rare cases// ... these findings should not make people shy away from ... study by the Institute for Clinical Evaluative Sciences (ICES), ... referring to the risk of Guillain-Barre syndrome (GBS). He ...
... improve the use of continuous positive airway pressure// (CPAP) ... study published in the November issue of CHEST, the ... (ACCP), finds that patients with OSA who were given ... their CPAP machines than patients with OSA taking a ...
... weight-loss surgery, obesity surgery and gastric-bypass surgery. In- hospital ... The mortality rate as per records is 2 per ... company, conducted a study on bariatric surgery complication rates ... in hospitals in accordance with their ratings. ...
... that lead to dehydration can signal a future attack for ... American// College of Rheumatology Annual Scientific Meeting in Washington DC. ... causes severe pain and swelling of the joints. The attacks, ... few days, most often the big toe, can also generate ...
Cached Medicine News:Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Rare Neurological Disorder Linked to Flu shot 2Health News:Research Questions Use of Sleep Meds for Patients with Apnea 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 3Health News:It's the Heat and the Humidity: How Each Worsens Gout Symptoms 2
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Plus cylinders only trial lens set....
Magnets move the color disks, Protects Disks from fingerprints, Keeps all the disks in one place, Clear glass insures accurate color perception, Makes Color testing fun....
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: